Floatz logo

Rivoceranib

Liver Cancer (Primary and Metastatic)

Affiliated Hospital of Guangdong Medical UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Liver Cancer (Primary and Metastatic) cohort.

Asset / SponsorPhaseRating
Adebrelimab
Affiliated Hospital of Guangdong Medical University
Phase 2CCC
EBNK-001
Essen Biotech
Phase 1/2CC
il-15
Essen Biotech
Phase 1/2CC

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →